Cardio3 BioSciences SA has acquired a portfolio of immuno-oncology assets in the US thereby expanding its therapeutic focus to cancer in addition to cardiovascular medicine. The Belgium-based company specialises in regenerative medicine. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News Regenerative Medicine
